Eli Lilly 2007 Annual Report Download - page 8
Download and view the complete annual report
Please find page 8 of the 2007 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2 -
3 -
4 -
5 -
6 -
7 -
8 -
9 -
10 -
11 -
12 -
13 -
14 -
15 -
16 -
17 -
18 -
19 -
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58
-
59
-
60
-
61
-
62
-
63
-
64
-
65
-
66
-
67
-
68
-
69
-
70
-
71
-
72
-
73
-
74
-
75
-
76
-
77
-
78
-
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
 |
 |
6
Innovation at Lilly: The Portfolio and the Pipeline
Major Marketed Products (Dates indicate the year of first global launch)
2005 Byetta® for type 2 diabetes
for use in combination with a thiazolidinedione (2007)
(in collaboration with Amylin Pharmaceuticals, Inc.)
2004 Cymbalta® for major depressive disorder
for diabetic peripheral neuropathic pain (2004)
for generalized anxiety disorder (2007)
for the maintenance treatment of major depressive disorder (2007)
(in collaboration with Quintiles Transnational Corp. in the U.S., Shionogi & Co. Ltd. in
Japan, and with Boehringer Ingelheim elsewhere in the world)
2004 Alimta® for malignant pleural mesothelioma
for second-line treatment of non-small cell lung cancer (2004)
2004 Symbyax® for bipolar depression
2004 Yentreve® for stress urinary incontinence (approved and launched outside the U.S.)
2003 Cialis® for erectile dysfunction
for once-daily use (2007)
2003 Strattera® for attention-decit hyperactivity disorder in children, adolescents, and adults
2002 Forteo® for treatment of men and postmenopausal women with osteoporosis who are at
high risk for a fracture
2001 Xigris® for severe sepsis in adult patients at high risk of death
1999 Actos® for type 2 diabetes
(in collaboration with Takeda outside the U.S.)
1998 Evista® for prevention of osteoporosis in postmenopausal women
for treatment of osteoporosis in postmenopausal women (1999)
for reduction in risk of invasive breast cancer in postmenopausal women with
osteoporosis (2007)
for reduction in risk of invasive breast cancer in postmenopausal women at high risk for
invasive breast cancer (2007)
1996 Zyprexa® for schizophrenia
for acute bipolar mania (2000)
Zyprexa® Zydis® tablet (2000)
for schizophrenia maintenance (2001)
as combination therapy with lithium or valproate for acute bipolar mania (2002)
for bipolar maintenance (2003)
Rapid-acting IntraMuscular formulation (2004)
Zyprexa® granules (2004; launched in Japan only)
1996 Humalog® Lyspro Rapid Acting Insulin for treatment of type 1 and type 2 diabetes
Humalog® Mix 75/25 (1999)
Humalog® Mix 50/50 (1999)
1995 Gemzar® for non-small-cell lung cancer
for pancreatic cancer (1996)
for bladder cancer (1999; approved and launched outside the U.S.)
for metastatic breast cancer (2003)
for recurrent ovarian cancer (2004)
for biliary tract cancer (2006; Japan)